210 related articles for article (PubMed ID: 22083523)
1. Predictive value of MGMT, hMLH1, hMSH2 and BRCA1 protein expression for pathological complete response to neoadjuvant chemotherapy in basal-like breast cancer patients.
Nakai K; Mitomi H; Alkam Y; Arakawa A; Yao T; Tokuda E; Saito M; Kasumi F
Cancer Chemother Pharmacol; 2012 Apr; 69(4):923-30. PubMed ID: 22083523
[TBL] [Abstract][Full Text] [Related]
2. Protein expression and methylation of DNA repair genes hMLH1, hMSH2, MGMT and BRCA1 and their correlation with clinicopathological parameters and prognosis in basal-like breast cancer.
Alkam Y; Mitomi H; Nakai K; Himuro T; Saito T; Takahashi M; Arakawa A; Yao T; Saito M
Histopathology; 2013 Nov; 63(5):713-25. PubMed ID: 24004112
[TBL] [Abstract][Full Text] [Related]
3. Expression of DNA mismatch repair proteins MLH1, MSH2, and MSH6 in recurrent glioblastoma.
Stark AM; Doukas A; Hugo HH; Hedderich J; Hattermann K; Maximilian Mehdorn H; Held-Feindt J
Neurol Res; 2015 Feb; 37(2):95-105. PubMed ID: 24995467
[TBL] [Abstract][Full Text] [Related]
4. Loss of expression of DNA repair enzymes MGMT, hMLH1, and hMSH2 during tumor progression in gastric cancer.
Kitajima Y; Miyazaki K; Matsukura S; Tanaka M; Sekiguchi M
Gastric Cancer; 2003; 6(2):86-95. PubMed ID: 12861399
[TBL] [Abstract][Full Text] [Related]
5. Expression of DNA repair proteins, MSH2, MLH1 and MGMT in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients' survival.
Theocharis S; Klijanienko J; Giaginis C; Rodriguez J; Jouffroy T; Girod A; Point D; Tsourouflis G; Sastre-Garau X
J Oral Pathol Med; 2011 Mar; 40(3):218-26. PubMed ID: 21029181
[TBL] [Abstract][Full Text] [Related]
6. The expression of mismatch repair proteins MLH1, MSH2 and MSH6 correlates with the Ki67 proliferation index and survival in patients with recurrent glioblastoma.
Stark AM; Doukas A; Hugo HH; Mehdorn HM
Neurol Res; 2010 Oct; 32(8):816-20. PubMed ID: 20223108
[TBL] [Abstract][Full Text] [Related]
7. Abnormal expression of BRCA1 and BRCA1-interactive DNA-repair proteins in breast carcinomas.
Yoshikawa K; Ogawa T; Baer R; Hemmi H; Honda K; Yamauchi A; Inamoto T; Ko K; Yazumi S; Motoda H; Kodama H; Noguchi S; Gazdar AF; Yamaoka Y; Takahashi R
Int J Cancer; 2000 Oct; 88(1):28-36. PubMed ID: 10962436
[TBL] [Abstract][Full Text] [Related]
8. Hypomethylation of mismatch repair genes MLH1 and MSH2 is associated with chemotolerance of breast carcinoma: Clinical significance.
Dasgupta H; Islam S; Alam N; Roy A; Roychoudhury S; Panda CK
J Surg Oncol; 2019 Jan; 119(1):88-100. PubMed ID: 30481381
[TBL] [Abstract][Full Text] [Related]
9. Mismatch repair protein expression is an independent prognostic factor in sporadic colorectal cancer.
Ohrling K; Edler D; Hallström M; Ragnhammar P
Acta Oncol; 2010 Aug; 49(6):797-804. PubMed ID: 20307245
[TBL] [Abstract][Full Text] [Related]
10. Significance of mismatch repair protein expression in the chemotherapeutic response of sporadic invasive ductal carcinoma of the breast.
Son BH; Ahn SH; Ko CD; Ka IW; Gong GY; Kim JC
Breast J; 2004; 10(1):20-6. PubMed ID: 14717755
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemistry of proteins for DNA mismatch repair in correlation to prognostic factors of mammarian cancer.
Köster F; Schröer A; Fischer D; Horn AK; Diedrich K; Friedrich M
Oncol Rep; 2007 May; 17(5):1223-7. PubMed ID: 17390069
[TBL] [Abstract][Full Text] [Related]
12. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH
Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemotherapy-induced changes in immunohistochemical expression of estrogen receptor, progesterone receptor, HER2, and Ki-67 in patients with breast cancer.
Avci N; Deligonul A; Tolunay S; Cubukcu E; Fatih Olmez O; Ulas A; Hartavi M; Kurt E; Evrensel T
J BUON; 2015; 20(1):45-9. PubMed ID: 25778295
[TBL] [Abstract][Full Text] [Related]
14. Expression of DNA repair proteins MSH2, MLH1 and MGMT in human benign and malignant thyroid lesions: an immunohistochemical study.
Giaginis C; Michailidi C; Stolakis V; Alexandrou P; Tsourouflis G; Klijanienko J; Delladetsima I; Theocharis S
Med Sci Monit; 2011 Feb; 17(3):BR81-90. PubMed ID: 21358597
[TBL] [Abstract][Full Text] [Related]
15. Influence of Helicobacter pylori infection on the expression of MLH1 and MGMT in patients with chronic gastritis and gastric cancer.
Bartchewsky W; Martini MR; Squassoni AC; Alvarez MC; Ladeira MS; Salvatore DM; Trevisan MA; Pedrazzoli J; Ribeiro ML
Eur J Clin Microbiol Infect Dis; 2009 Jun; 28(6):591-7. PubMed ID: 19089477
[TBL] [Abstract][Full Text] [Related]
16. MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early-stage lung cancer patients from the IFCT-0002 Phase 3 Trial.
Levallet G; Dubois F; Fouret P; Antoine M; Brosseau S; Bergot E; Beau-Faller M; Gounant V; Brambilla E; Debieuvre D; Molinier O; Galateau-Sallé F; Mazieres J; Quoix E; Pujol JL; Moro-Sibilot D; Langlais A; Morin F; Westeel V; Zalcman G
Oncotarget; 2017 Jan; 8(3):4313-4329. PubMed ID: 28008145
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of DNA repair proteins MLH1, MSH2 and MGMT expression in non-small-cell lung cancer and precursor lesions.
Cooper WA; Kohonen-Corish MR; Chan C; Kwun SY; McCaughan B; Kennedy C; Sutherland RL; Lee CS
Histopathology; 2008 Apr; 52(5):613-22. PubMed ID: 18370958
[TBL] [Abstract][Full Text] [Related]
18. Assessment of predictive markers of response to neoadjuvant chemotherapy in breast cancer.
Tewari M; Pradhan S; Singh U; Singh TB; Shukla HS
Asian J Surg; 2010 Oct; 33(4):157-67. PubMed ID: 21377101
[TBL] [Abstract][Full Text] [Related]
19. Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas.
Felsberg J; Thon N; Eigenbrod S; Hentschel B; Sabel MC; Westphal M; Schackert G; Kreth FW; Pietsch T; Löffler M; Weller M; Reifenberger G; Tonn JC;
Int J Cancer; 2011 Aug; 129(3):659-70. PubMed ID: 21425258
[TBL] [Abstract][Full Text] [Related]
20. Pathological predictive factors for tumor response in locally advanced breast carcinomas treated with anthracyclin-based neoadjuvant chemotherapy.
Patel T; Gupta A; Shah M
J Cancer Res Ther; 2013; 9(2):245-9. PubMed ID: 23771367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
